Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study

Leggi l'articolo originale


Journal of Clinical Oncology, Ahead of Print.

Lascia un commento